

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4373871

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
AXERION THERAPEUTICS, INC.	04/17/2017

RECEIVING PARTY DATA

Name:	CONNECTICUT INNOVATIONS, INCORPORATED
Street Address:	865 BROOK STREET
City:	ROCKY HILL
State/Country:	CONNECTICUT
Postal Code:	06067
Name:	ERIKA R. SMITH
Street Address:	63 COLONY ROAD
City:	WESTPORT
State/Country:	CONNECTICUT
Postal Code:	06880

PROPERTY NUMBERS Total: 15

Property Type	Number
Application Number:	60762487
Application Number:	60831659
Application Number:	12162256
Application Number:	14146345
Application Number:	14670723
Application Number:	12922370
Application Number:	12597535
Application Number:	11994978
Application Number:	12335328
Application Number:	11055163
Application Number:	11544013
Application Number:	10735256
Application Number:	14088158
Application Number:	12693940
Application Number:	09972599

PATENT

CORRESPONDENCE DATA**Fax Number:** (860)548-2680*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 8605095347**Email:** cguilmette@uks.com**Correspondent Name:** GREGG J. LALLIER, ESQUIRE**Address Line 1:** 100 PEARL STREET**Address Line 2:** UPDIKE, KELLY & SPELLACY, P.C.**Address Line 4:** HARTFORD, CONNECTICUT 06103

NAME OF SUBMITTER:	CHRISTINE GUILMETTE
SIGNATURE:	/Christine Guilmette/
DATE SIGNED:	04/19/2017
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 10

source=Intellectual Security Agreement#page1.tif
source=Intellectual Security Agreement#page2.tif
source=Intellectual Security Agreement#page3.tif
source=Intellectual Security Agreement#page4.tif
source=Intellectual Security Agreement#page5.tif
source=Intellectual Security Agreement#page6.tif
source=Intellectual Security Agreement#page7.tif
source=Intellectual Security Agreement#page8.tif
source=Intellectual Security Agreement#page9.tif
source=Intellectual Security Agreement#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this "**Agreement**") is made as of April 17, 2017 by **AXERION THERAPEUTICS, INC.**, a Delaware corporation ("**Debtor**"), for the benefit of the Agent (as defined by the Security Agreement) and the Secured Parties (as defined by the Security Agreement) under the Security Agreement (as defined below).

WITNESSETH

WHEREAS, pursuant to that certain Security Agreement among Debtor, the Agent and Secured Parties dated as of the date hereof (as amended and in effect from time to time, the "**Security Agreement**"), Debtor has granted to the Secured Party a security interest in the Collateral (as defined by the Security Agreement), including without limitation the Domain Names, Trademarks, Patents, Patent Rights, and Copyrights (each as defined herein), listed on **Schedule A** attached hereto, all to secure the payment and performance of the Obligations (as defined in the Security Agreement); and

WHEREAS, this Agreement is supplemental to the provisions contained in the Security Agreement.

NOW, THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **DEFINITIONS.** Unless otherwise defined herein, terms which are defined in the Security Agreement and used herein are so used as so defined. The following terms shall have the following meanings:

"**Copyrights**" means (a) all copyrights of the United States or any other country, including, without limitation, any thereof referred on **Schedule A** attached hereto; and (b) all copyright registrations filed in the United States or in any other country, including, without limitation, any thereof referred to on **Schedule A** attached hereto.

"**Domain Names**" means all domain names and domain name registration applications, that are owned by Debtor or in which Debtor has any right, title or interest, now or in the future, including but not limited to all derivatives or variations, whether authorized or unauthorized, including those listed on **Schedule A** attached hereto.

"**ICANN**" means the Internet Corporation for Assigned Names and Numbers.

"**Patents**" means (a) all letters patent of the United States and all reissues and extensions thereof; and (b) all applications for letters patent of the United States and all divisions, continuations and continuations-in-part thereof or any other country, including, without limitation, any thereof referred to on **Schedule A** attached hereto.

“**Patent Rights**” means rights held to Patents under license agreements referred to on Schedule A attached hereto.

“**Registry**” means, as applicable, (i) any domain name registry with whom the Domain Names are registered, (ii) the U.S. Copyright Office or any comparable office of any foreign jurisdiction with whom Copyrights are registered, or (iii) the U.S. Patent & Trademark Office or any comparable office of any state or foreign jurisdiction with whom Trademarks or Patents are registered.

“**Trademarks**” means (a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether registered in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof or otherwise, including, without limitation, any thereof referred to on Schedule A attached hereto; (b) all renewals thereof; and (c) all goodwill of the business connected with the use of and symbolized by the Trademarks.

2. SECURITY INTEREST.

2.1. Security Interest. As collateral security for the payment and performance in full of all of the Obligations, Debtor hereby unconditionally grants to the Agent, for the ratable benefit of all Secured Parties, a continuing security interest in and first priority lien on the Domain Names, Trademarks, Patents and Copyrights that constitute Collateral, and all Proceeds (as defined in the Security Agreement) of any of the foregoing. Debtor hereby authorizes the Agent to take other appropriate steps to transfer effective ownership and control of such Domain Names, Trademarks, Patents and Copyrights, with the respective Registry upon the occurrence and during the continuance of an Event of Default and the exercise of the remedies of the Agent and/or any Secured Party under this Agreement and the Security Agreement.

2.2. Supplemental Security Agreement. Pursuant to the Security Agreement, Debtor has granted to the Agent and Secured Parties, a continuing security interest in and lien on the Collateral (including certain Domain Names, Trademarks, Patents and Copyrights). The Security Agreement, and all rights and interests of the Agent and Secured Parties in and to the Collateral (including such Domain Names, Trademarks, Patents and Copyrights) thereunder, are hereby ratified and confirmed in all respects, and are hereby incorporated herein by reference thereto. In no event shall this Agreement, the grants hereunder, or the recordation of this Agreement (or any document hereunder) with the respective Registry, adversely affect or impair, in any way or to any extent, the Security Agreement, the security interest of the Agent and/or any Secured Party in the Collateral (including the Domain Names, Trademarks, Patents and Copyrights that constitute Collateral) pursuant to the Security Agreement and this Agreement, the attachment and perfection of such security interest under the UCC (including the security interest in such Domain Names, Trademarks, Patents and Copyrights), or any present or future rights and interests of the Agent and/or any Secured Party in and to the Collateral under or in connection with the Security Agreement, this Agreement or the UCC.

Any and all rights and interests of the Agent and/or any Secured Party in and to the Domain Names, Trademarks, Patents and Copyrights that constitute Collateral (and any and all Obligations of Debtor with respect to such Domain Names, Trademarks, Patents and Copyrights) provided herein, or arising hereunder or in connection herewith, shall only supplement and be cumulative and in addition to the rights and interests of the Agent and Secured Parties (and the Obligations of Debtor) in, to or with respect to the Collateral (including such Domain Names, Trademarks, Patents and Copyrights) provided in or arising under or in connection with the Security Agreement and shall not be in derogation thereof. NEITHER THE AGENT NOR ANY SECURED PARTY ASSUMES ANY LIABILITY ARISING IN ANY WAY BY REASON OF HOLDING SUCH COLLATERAL.

3. AFTER-ACQUIRED DOMAIN NAMES, ETC.

3.1. After-Acquired Domain Names, Copyrights, Trademarks and Patents. If, before the Obligations shall have been finally paid and satisfied in full, Debtor shall obtain any right, title or interest in or to any other or new Domain Names, Trademarks, Copyrights or Patents that constitute Collateral, or become entitled to the benefit of any such Domain Names, Trademarks, Copyrights or Patents or any variation or improvement on any of such Domain Name Collateral, the provisions of this Agreement and the Security Agreement shall automatically apply thereto and Debtor shall promptly give to the Agent notice thereof in writing and execute and deliver to the Agent such documents or instruments as the Agent may reasonably request further to implement, preserve or evidence the interests of the Agent and Secured Parties therein.

3.2. Amendment to Schedule. Debtor authorizes the Agent to modify this Agreement, without the necessity of Debtor's further approval or signature, by amending **Schedule A** hereto to include any future or other Domain Names, Trademarks, Copyrights or Patents under Section 2 or Section 3 hereof that constitute Collateral and/or to delete Domain Names, Trademarks, Copyrights or Patents terminated by Debtor pursuant to the Security Agreement.

4. NO ASSUMPTION OF LIABILITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, NEITHER THE AGENT NOR ANY SECURED PARTY ASSUMES ANY LIABILITIES OF THE DEBTOR WITH RESPECT TO ANY CLAIM OR CLAIMS REGARDING THE DEBTOR'S OWNERSHIP OR PURPORTED OWNERSHIP OF, OR RIGHTS OR PURPORTED RIGHTS ARISING FROM, ANY OF THE DOMAIN NAMES, COPYRIGHTS, TRADEMARKS OR PATENTS THAT CONSTITUTE COLLATERAL, OR ANY PRACTICE, USE, LICENSE OR SUBLICENSE THEREOF, WHETHER ARISING OUT OF ANY PAST, CURRENT OR FUTURE EVENT, CIRCUMSTANCE, ACT OR OMISSION OR OTHERWISE. ALL OF SUCH LIABILITIES SHALL BE EXCLUSIVELY BORNE BY THE DEBTOR, AND THE DEBTOR SHALL INDEMNIFY THE AGENT AND EACH SECURED PARTY FOR ANY AND ALL COSTS, EXPENSES, DAMAGES AND CLAIMS, INCLUDING LEGAL FEES, INCURRED BY THE AGENT AND/OR ANY SECURED PARTY WITH RESPECT TO SUCH LIABILITIES.

5. **RIGHTS AND REMEDIES CUMULATIVE.** The rights and remedies of the Agent and Secured Parties with respect to the Domain Names, Copyrights, Trademarks and Patents that constitute Collateral, whether established hereby, by the Security Agreement or by any other agreements or by law, shall be cumulative and may be exercised singularly or concurrently. This Agreement is supplemental to the Security Agreement, and nothing contained herein shall in any way derogate from any of the rights or remedies of the Agent and/or any Secured Party contained therein. Nothing contained in this Agreement shall be deemed to extend the time of attachment or perfection of or otherwise impair the security interest in any of the Collateral granted to the Agent and/or any Secured Party, under the Security Agreement.

6. **AMENDMENT AND WAIVER.** This Agreement may only be amended, and any provision hereunder may only be waived, pursuant to the Security Agreement.

7. **FILINGS.** The Agent may at any time and from time to time, at Debtor's expense, file, or have Agent's representatives or agents file, a copy of this Agreement with the United States Patent & Trademark Office, the U.S. Copyright Office or any other filing authority.


8. **COUNTERPARTS.** This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall constitute a complete and original instrument but all of which together shall constitute one and the same agreement (notwithstanding that all of the parties are not signatories to the original or the same counterpart, or that signature pages from different counterparts are combined), and it shall not be necessary when making proof of this Agreement or any counterpart thereof to account for any other counterpart, and the signature of any party to any counterpart shall be deemed to be a signature to and may be appended to any other counterpart. For purposes of this Agreement, a document (or signature page thereto) signed and transmitted by facsimile machine or other electronic means is to be treated as an original document. The signature of any party on any such document, for purposes hereof, is to be considered as an original signature, and the document transmitted is to be considered to have the same binding effect as an original signature on an original document. At the request of any party, any facsimile or other electronic signature is to be re-executed in original form by the party which executed the facsimile or other electronic signature. No party may raise the use of a facsimile machine or other electronic means, or the fact that any signature was transmitted through the use of a facsimile machine or other electronic means, as a defense to the enforcement of this Agreement.

[INTENTIONALLY LEFT BLANK – SIGNATURE PAGE FOLLOWS]

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the foregoing Intellectual Property Security Agreement is signed and delivered on the date first set forth above.

AXERION THERAPEUTICS, INC.

By:  Digitally signed by George D. Maynard
DN: cn=George D. Maynard, o=Axerion Therapeutics,
ou, email=gmaynard@axeriontherapeutics.com, c=US
Date: 2017.04.13 14:38:41 -04'00'

Name: George D. Maynard,
Title: President & CSO

Schedule A – Registered IP

Trademarks

Marks	Brief Description	Mark Type	Class	Serial Number	Filing Date	Registration
N/A						

Patents Under License to Axerion

Application Title	Application Type	Application Number	Application Filing Date	Case Status	Country
NOGO RECEPTOR ANTAGONISTS	PCT	PI0707276-7	1/26/2007	Pending	Brazil
NOGO RECEPTOR ANTAGONISTS	PCT	2640423	1/26/2007	Pending	Canada
NOGO RECEPTOR	PCT	200780010338.3	1/26/2007	Pending	China (People's Republic)
NOGO RECEPTOR	DIV	201210593895.5	1/26/2007	Pending	China (People's Republic)
NOGO RECEPTOR	PCT	07762730.5	1/26/2007	Pending	European Patent Convention
NOGO RECEPTOR	DIV	12162911.7	1/26/2007	Pending	European Patent Convention
NOGO RECEPTOR ANTAGONISTS	PCT	2008-552443	1/26/2007	Pending	Japan
NOGO RECEPTOR ANTAGONISTS	DIV	2012-266674	1/26/2007	Pending	Japan
NOGO RECEPTOR ANTAGONISTS	DIV	2014-168201	1/26/2007	Pending	Japan

NOGO RECEPTOR ANTAGONISTS	PCT	MX/a/2008/009620	1/26/2007	Issued	Mexico
NOGO RECEPTOR ANTAGONISTS	DIV	MX/a/2012/000864	1/26/2007	Issued	Mexico
NOGO RECEPTOR ANTAGONISTS	ORD	US07/02199	1/26/2007	National	Patent Cooperation Treaty
NOGO RECEPTOR ANTAGONISTS	PRO	60/762487	1/26/2006	Converted	United States
NOGO RECEPTOR ANTAGONISTS	PRO	60/831659	7/19/2006	Converted	United States
NOGO RECEPTOR ANTAGONISTS	PCT	12/162256	1/26/2007	Issued	United States
NOGO RECEPTOR ANTAGONISTS	CON	14/146345	1/2/2014	Pending	United States
Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury	CON	14/670,723	3/27/2015	To Be Filed	United States
Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury	RCE Request For Cont. Exam	12/922,370	9/13/2010	Allowed	United States
Reactivation of Axon Growth and Recovery in Chronic Spinal Cord	FOR - Foreign	9720418.4	9/13/2010	Pending	Europe
NGR Variants and Compositions Thereof for Suppressing Axonal	371 (Nat Phase US)	11/994,978	7/14/2008	Issued	United States
NOGO Receptor Antagonist	DIV - Divisional	12/335,328	12/15/2008	Issued	United States

NOGO Receptor Antagonist	371 (Nat. Phase US)	11/055,163	2/10/2005	Issued	United States
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	United Kingdom
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Sweden
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Netherlands
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Italy
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Ireland
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	France
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Spain
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Europe
NOGO Receptor Antagonist	FOR - Foreign	60332842.3-08	2/10/2005	Issued	Germany
NOGO Receptor Antagonist	FOR - Foreign	3785123.5	2/10/2005	Issued	Switzerland
NOGO Receptor Homologs	DIV - Divisional	11/544,013	10/6/2006	Issued	United States
NOGO Receptor Homologs	CON - Continuation	10/735,256	12/12/2003	Issued	United States
NOGO Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	United Kingdom
NOGO Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	Sweden
NOGO Receptor Homologs	FOR - Foreign	2002-532629	4/6/2003	Issued	Japan
NOGO Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	Italy

Nogo Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	France
Nogo Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	Spain
Nogo Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	Europe
Nogo Receptor Homologs	FOR - Foreign	60141409.8.08	4/6/2003	Issued	Germany
Nogo Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	Switzerland
Nogo Receptor Homologs	FOR - Foreign	1979595.4	4/6/2003	Issued	Austria
Nogo Mediated Blockade of Axonal	Receptor- DIV - Divisional	14/088,158	11/22/2013	Pending	United States
Nogo Mediated Blockade of Axonal	Receptor- DIV - Divisional	12/693,940	1/26/2010	Issued	United States
Nogo Mediated Blockade of Axonal Growth	Receptor- CIP - Continuation In Part	09/972,599	10/6/2001	Issued	United States
Nogo Mediated Blockade of Axonal	Receptor- FOR - Foreign	1942367.2	7/12/2003	Issued	United Kingdom
Nogo Mediated Blockade of Axonal	Receptor- FOR - Foreign	2003-534444	4/6/2004	Issued	Japan
Nogo Mediated Blockade of Axonal	Receptor- FOR - Foreign	2001-551104	7/12/2003	Issued	Japan
Nogo Mediated Blockade of Axonal	Receptor- FOR - Foreign	1942367.2	7/12/2003	Issued	Italy
Nogo Mediated Blockade of Axonal	Receptor- FOR - Foreign	1942367.2	7/12/2003	Issued	Ireland
Nogo Mediated Blockade of Axonal	Receptor- FOR - Foreign	1942367.2	7/12/2003	Issued	France

Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	1942367.2	7/12/2003	Issued	Spain
Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	1942367.2	7/12/2003	Issued	Europe
Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	1942367.2	7/12/2003	Issued	Germany
Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	1804940	7/12/2003	Issued	China
Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	1942367.2	7/12/2003	Issued	Switzerland
Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	2,461,655	4/6/2004	Pending	Canada
Nogo Mediated Blockade of Axonal	Receptor	FOR - Foreign	2,397,199	7/12/2003	Issued	Canada

Domain Names

Domain Name	Expires	Purpose
axeriontherapeutics.com	8/3/2016	website/e-mail

Copyrights

Copyright	Reg No.	Description
N/A		